EMA finds no suicide risk with GLP-1 diabetes, obesity drugs

There is no evidence of an increased risk of suicidal or self-injurious thoughts and actions with GLP-1 agonists used to treat diabetes and obesity, according to the EU me

Lilly to invest $2.5bn for obesity, diabetes drug production

Eli Lilly has followed Novo Nordisk in announcing a big investment in its manufacturing network, intended to meet anticipated strong future demand for diabetes and obesity

EMA finds no evidence GLP-1 agonists cause thyroid cancer

The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’

FDA ends 7-year obesity drug drought, clearing Novo Nordisk'...

Novo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which it believes has the potential to redefine the market for weight-loss medicine

Trial win sets up filings for Lilly's diabetes blockbuster h...

Eli Lilly has scored five out of five with its phase 3 trials of type 2 diabetes candidate tirzepatide, setting up regulatory filings for a drug that the drugmaker thinks could be the lynch

Lilly raises 2020 earnings forecast on pandemic stockpiling